CA2606288A1 — Subtituted heteroaryl cb1 antagonists
Assigned to Individual · Expires 2006-10-26 · 20y expired
What this patent protects
Compounds of Formula (I) are provided. In which the variables are as described herein. Such compounds may be used to modulate CBl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CBl modulation in humans, domesticated companio…
USPTO Abstract
Compounds of Formula (I) are provided. In which the variables are as described herein. Such compounds may be used to modulate CBl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CBl modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such Iigands for receptor localization studies and various in vitro assays.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.